On November 12, 2026, the Board of Directors of Liquidia Corporation, a Delaware corporation (the “Company”), appointed Russell Schundler as the Company’s Chief Strategy Officer and General Counsel, effective November 16, 2026 (the “Effective Date”). Mr. Schundler has served as the Company’s General Counsel since March 2021. Effective upon Mr. Schundler’s appointment as Chief Strategy Officer and General Counsel, his annual base compensation was increased to $625,000 and his target bonus was increased to 60% of his annual base compensation. In addition, Mr. Schundler was granted a number of restricted stock units (the “RSUs”) under the Company’s 2020 Long-Term Incentive Plan (the “Plan”) equal to $500,000 divided by the Fair Market Value (as defined in the Plan) of a share of the Company’s common stock as of the Effective Date. The RSUs (i) are subject to the terms of the Plan and the form of award agreement and (ii) vest as follows: 25% of the grant will become vested on January 11, 2028, and the balance will become vested in equal quarterly installments over the following three years, subject to Mr. Schundler’s continuous employment with the Company on each such vesting date.
|
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for rare respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company generates revenue through the sale of YUTREPIA (treprostinil) inhalation powder, a dry powder formulation designed using its proprietary PRINT technology to enhance deep lung delivery, and through a profit-sharing agreement with Sandoz for the sale of generic treprostinil injection in the United States. Liquidia operates through its wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen. Its pipeline includes L606, a liposomal formulation of treprostinil licensed from Pharmosa Biopharm Inc., which is being evaluated for PAH and PH-ILD. The company serves healthcare providers and patients in the United States, utilizing a targeted commercial field force to support the treatment of these conditions. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage liquidia.com |
| Sector Healthcare | IR page liquidia.com/investors | |
|
Tags
pulmonary arterial hypertension, pulmonary hypertension, interstitial lung disease, inhaled therapies, dry powder inhalers, treprostinil, drug delivery, rare diseases, cardiopulmonary disease, liposomal formulations, YUTREPIA, Treprostinil Injection, L606, PRINT technology, Liquidia Technologies Inc., Liquidia PAH LLC, RareGen, Pharmosa Biopharm Inc., Sandoz Inc.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 3.875B |
| Market cap (USD) | $ 3.875B |
| P/E | -35.99 |
| PEG | — |
| P/BV | -152.37 |
| P/S | 6.23 |
| P/OCF | 11.96 |
| P/FCF | 13.31 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -113.0% |
| ROI | -29.2% |
| ROIC | -16.3% |
| Profit margin | -43.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 427.6% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 18 |
| Quality score | -33.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.32M | 13.996M | 17.488M | 15.935M | 12.853M | 739.628K | 8.072M | 2.707M | 7.258M |
| Net profit | -68.924M | -130.394M | -78.502M | -41.015M | -34.579M | -59.763M | -47.583M | -53.136M | -29.154M |
| Free cash flow | -40.022M | -98.371M | -42.854M | -29.18M | -34.143M | -54.897M | -50.133M | -32.701M | -26.834M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | — | 1.62M | 272,557 | — | 0.00 | 2.99M | 5.02M | 4.06M | 2.72M | 54.1M |
| ↳ YoY growth | -83.2% | +67.8% | -19.1% | -33.0% | +1,889.4% | |||||
| ↳ 5y CAGR | +25.3% | +71.6% | ||||||||
| Borrowings, current (USD) | — | 15.6M | 316,906 | 5.59M | 0.00 | — | — | — | — | — |
| Borrowings, non-current (USD) | — | 5.56M | 11.6M | 10.3M | 10.3M | 10.4M | 19.9M | — | — | — |
| Lease liabilities (USD) | — | — | 6.66M | 8.54M | 6.85M | 5.67M | 4.58M | 3.5M | 6.94M | — |
| Cash and deposits (USD) | 1.44M | 3.42M | 39.5M | 55.8M | 65.3M | 57.5M | 93.3M | 83.7M | 176M | 191M |
| Intangible assets (USD) | — | — | — | 0.00 | 5.53M | 4.39M | 3.73M | 3.43M | 3.16M | 2.95M |
| Right-of-use assets (USD) | — | — | 3.99M | 2.82M | 2.65M | 2.41M | 2.1M | 1.7M | 4.19M | 3.95M |
| Net debt (borrowings + leases - cash) (USD) | — | 17.7M | -27.6M | -31.4M | -48.2M | -41.4M | -68.8M | — | — | — |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | — | -24.3M | -31.8M | -48.3M | -54.1M | -34M | -28.6M | -41.6M | -93.4M | -35.7M |
| Purchases of property, plant and equipment (USD) | — | -2.54M | -870,943 | -1.85M | -752,086 | -107,220 | -592,000 | -1.29M | -4.95M | -4.34M |
| Change in receivables (cash effect) (USD) | — | -328,458 | 1.35M | 272,557 | 0.00 | -2.99M | -2.03M | 956,000 | 1.34M | -51.4M |
| Change in inventories (cash effect) (USD) | — | — | — | — | — | — | — | — | -241,000 | -23M |
| Change in payables (cash effect) (USD) | — | 1.87M | -1.28M | 294,514 | -297,160 | -7.56M | 814,000 | -1.15M | 2.33M | -2.59M |
| Interest paid (cash effect) (USD) | — | -313,390 | -1.09M | -887,038 | -820,889 | -423,230 | -1.63M | -360,000 | — | — |
| Income taxes paid (cash effect) (USD) | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Share-based compensation (USD) | — | 514,092 | 2.2M | 3.38M | 3.95M | 6.75M | 9.3M | 10.1M | 18.8M | 29.5M |
| Operating cash flow before change in receivables (USD) | — | -24M | -33.2M | -48.6M | -54.1M | -31M | -26.6M | -42.5M | -94.8M | 15.7M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -26.8M | -32.7M | -50.1M | -54.9M | -34.1M | -29.2M | -42.9M | -98.4M | -40M |
| Income detail | ||||||||||
| Research and development expense (USD) | — | 24.8M | 28.7M | 40.5M | 32.2M | 20.5M | 19.4M | 43.2M | 47.8M | 39.3M |
| ↳ 5y CAGR | -4.7% | +8.5% | +3.4% | +4.0% | ||||||
| Total comprehensive income (USD) | — | -29.2M | -53.1M | -47.6M | — | — | — | — | — | — |
| Comprehensive income to owners (USD) | — | -29.2M | -53.1M | -47.6M | — | — | — | — | — | — |
| Reported | Aug 14, 2018 | Feb 26, 2019 | May 2, 2019 | Mar 25, 2021 | May 13, 2021 | Mar 17, 2022 | Mar 20, 2023 | Mar 5, 2026 | Mar 5, 2026 | Mar 5, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
· YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026
· October 2026 total patient shipments reached their highest monthly level since launch
· Resolved all litigation with United Therapeutics through a global settlement, securing continuity of care for all patients treated with YUTREPIA
· Recorded net loss of $236.3 million reflects a $389.7 million litigation settlement charge
· Fifth consecutive quarter of increasing non-GAAP, adjusted EBITDA to $140.5 million
· Increased cash and cash equivalents to $396.1 million prior to settlement payments
· Granted Fast Track designation to YUTREPIA for the treatment of SSc-RP and initiated RE-WARM, a Phase 2 randomized open-label dose-finding study
MORRISVILLE, N.C., November 10, 2026 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m.
November 3, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Aug 5, 2020 | Renamed | LIQUIDIA TECHNOLOGIES INC → LIQUIDIA CORP |
ETFs Holding Liquidia Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| JSML | 1.30% | 56,094 | $ 4.718M | Jul 31, 2026 |
| JSMD | 1.26% | 157,623 | $ 13.258M | Jul 31, 2026 |
| FSCC | 0.97% | 51,507 | $ 3.511M | Aug 31, 2026 |
| FSEG | 0.57% | 409 | $ 32.61K | Jun 30, 2026 |
| AFSM | 0.56% | 14,496 | $ 817.14K | Nov 16, 2026 |
| FTKI | 0.56% | 2,508 | $ 141.376K | Nov 16, 2026 |
| EHLS | 0.42% | 4,009 | $ 225.987K | Nov 17, 2026 |
| ESSC | 0.36% | 1,547 | $ 130.118K | Jul 31, 2026 |
| FESM | 0.30% | 214,691 | $ 17.117M | Jun 30, 2026 |
| HELX | 0.25% | 871 | $ 69.445K | Jun 30, 2026 |
| VFMO | 0.14% | 39,128 | $ 2.667M | Aug 31, 2026 |
| AFMC | 0.13% | 5,854 | $ 329.99K | Nov 16, 2026 |
| MKTN | 0.11% | 1,537 | $ 122.545K | Jun 30, 2026 |
| SHRT | 0.09% | 200 | $ 11.274K | Nov 17, 2026 |
| FTLS | 0.07% | 31,058 | $ 0.00 | Nov 16, 2026 |
| DFAS | 0.04% | 222,059 | $ 12.906M | Nov 12, 2026 |
| IALT short | -0.03% | -39,020 | $ -2.2M | Nov 16, 2026 |
| MSSM | 0.03% | 2,896 | $ 197.42K | Aug 31, 2026 |
| JSTC | 0.02% | 983 | $ 55.412K | Nov 17, 2026 |
| GVLU | 0.02% | 819 | $ 46.167K | Nov 17, 2026 |
| DCOR | 0.00% | 1,970 | $ 114.496K | Nov 12, 2026 |
| NTRL | 0.00% | 4,562 | $ 0.00 | Nov 16, 2026 |







